An industry first? OraVital places guarantee on product's effectiveness for treating gingivitis and mild to moderate periodontal disease
The OraVital System's results are guaranteed when applied to the diagnosis and treatment of gingivitis and mild to moderate periodontal disease.
During the 2017 Chicago Midwinter Meeting, OraVital (Toronto, Ontario) will unveil what the company is calling a "dental industry first"—a guarantee on the effectiveness of its OraVital System against gingivitis and periodontal disease.
Specifically, the system's results are guaranteed when applied to the diagnosis and treatment of gingivitis and mild to moderate periodontal disease. Under the terms of the guarantee, if despite following the OraVital System protocol there is not a noticeable improvement in the patient’s oral health (defined as an 87% and 79% to 84% reduction in BOP and pockets, respectively, with no pockets above 4 mm), the patient can be retested and retreated free of charge under the guidance of an OraVital Clinical Coach.
According toOraVital CEO James Hyland, DDS, “This is a first-of-a-kind guarantee that states, when used as directed by a OraVital Certified Clinic, the OraVital System will predictably control the biofilm and oral infections that cause gingivitis and mild to moderate periodontal disease with pockets less than or equal to 6 mm prior to treatment.”
According to OraVital, the key to the guarantee is the standardized training and implementation of OraVital’s proprietary, non-invasive protocol consisting of its BiofilmDNA microbiology test and corresponding lab analysis, which guides the clinician in prescribing the correct regimen of antibiotic/antifungal and antimicrobial rinses to effectively control pathogenic bacteria.
The OraVital System also includes the company’s recommended home-care regimen, which is specially designed to keep oral biofilm and pathogens under control. Dr. Hyland explains, "If the bacteria in the biofilm are controlled effectively by the practitioner in partnership with the patient, the oral infection is controlled. The OraVital System does this predictably."
Dr. Hyland adds, “With new research being published almost daily linking exposure to high risk periodontal pathogens to serious medical conditions such as heart disease, arthritis, Alzheimer’s disease, rheumatoid arthritis, and certain forms of cancer, it’s more important than ever for us to ensure that the OraVital System is being used properly on our patients.”
The OraVital System Guarantee will be officially extended to participating OraVital Certified Clinics throughout Canada and the United States on April 1. More information may be obtained by e-mailing Guarantee@OraVital.com or visiting OraVital at booth No. 1043 during the 2017 Chicago Midwinter Meeting.
Editor's note: This article represents an edited verson of an OraVital press release issued 14 February 2017.